Boardroom Alpha
Boardroom Alpha
HUM · Current Report (Form 8-K) · Filed April 20, 2026

Humana Inc — Current Report (Form 8-K)

Form
8-K
Filed
April 20, 2026
Period
Apr 16, 2026
Ticker
HUM
Accession
0000049071-26-000015
Boardroom Alpha · Filing insights

Humana shareholders elected all directors, approved PwC as auditor, backed executive pay, approved the Stock Plan, and rejected the parachute proposal.

About Humana Inc
Market cap
$38.5B
1Y TSR
+24.7%
3Y TSR
−14.4%
Board grade
C-
Sector
Healthcare
CEO
James A Rechtin
Last annual meeting: Apr 16, 2026 · View full Humana Inc profile →
hum-20260416


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 20, 2026 (April 16, 2026)
Humana Inc.
(Exact name of registrant as specified in its charter)
Delaware001-597561-0647538
(State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
101 East Main Street, Louisville, Kentucky 40202
(Address of principal executive offices, including zip code)

(502) 580-1000
(Registrant’s telephone number, including area code)


(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common StockHUMNew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  




Item 5.07. Submission of Matters to a Vote of Security Holders.

The regular annual meeting of the stockholders of Humana Inc. (the “Company”) was held on April 16, 2026 (the “Annual Meeting”), for the purpose of voting on the five (5) proposals detailed in the Company’s Proxy Statement. There were present at the Annual Meeting by valid proxy the holders of 107,941,773 shares of the Company’s common stock, constituting a quorum.

Proxies for the meeting were solicited pursuant to Section 14(a) of the Securities Exchange Act of 1934 and there was no solicitation in opposition to management’s nominees for directors. The voting results on each proposal submitted to the stockholders of the Company at the Annual Meeting are herein disclosed.

Proposal #1: Each of the ten (10) nominees for director were elected to the Company’s Board of Directors. The term of office for each director will be until the next annual meeting or until their successors shall be elected and qualified. The voting results for each director were as follows:
NameForAgainstAbstainedBroker Non-Votes
Raquel C. Bono, M.D.101,247,023852,333103,3725,739,045
Frank A. D’Amelio97,025,5215,065,710111,4975,739,045
David T. Feinberg, M.D.100,915,6741,169,313117,7415,739,045
Wayne A. I. Frederick, M.D.85,170,45216,912,783119,4935,739,045
Kurt J. Hilzinger98,144,4713,950,736107,5215,739,045
Karen W. Katz99,324,7082,762,723115,2975,739,045
Marcy S. Klevorn101,233,979854,134114,6155,739,045
Jorge S. Mesquita101,329,642742,426130,6605,739,045
James A. Rechtin101,367,406735,54099,7825,739,045
Gordon Smith101,021,6391,055,631125,4585,739,045

Proposal #2: The ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026, was approved. The voting results were as follows:
ForAgainstAbstainedBroker Non-Votes
102,433,6865,381,161126,926Not Applicable

Proposal #3: The non-binding, advisory vote with respect to the Company’s executive compensation was approved. The voting results were as follows:
ForAgainstAbstainedBroker Non-Votes
97,237,8514,669,732295,1455,739,045

Proposal #4: The vote with respect to the Humana Inc. 2026 Stock Incentive Plan was approved. The voting results were as follows:
ForAgainstAbstainedBroker Non-Votes
97,655,2004,295,549251,9795,739,045

Proposal #5: The vote with respect to a stockholder proposal requesting shareholder approval requirement for excessive golden parachutes was not approved. The voting results were as follows:
ForAgainstAbstainedBroker Non-Votes
41,970,89259,079,2791,152,5575,739,045



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
HUMANA INC.
BY:/s/ Valerie M. Talkers
Valerie M. Talkers
Vice President, Associate General Counsel & Corporate Secretary
Dated: April 20, 2026

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Humana Inc (HUM)

Reference

Frequently asked questions

When did Humana Inc file this 8-K?
Humana Inc (HUM) filed this Current Report (Form 8-K) with the SEC on April 20, 2026. The accession number assigned by EDGAR is 0000049071-26-000015.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Humana shareholders elected all directors, approved PwC as auditor, backed executive pay, approved the Stock Plan, and rejected the parachute proposal. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Humana Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Humana Inc has filed under CIK 49071, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer